Tumor necrosis is neither categorically good nor categorically bad. When tumor cells die and rupture in a disorganized fashion, the consequences depend heavily on context: whether the necrosis happened on its own or was triggered by treatment, which cancer type is involved, how much tissue is dying and how fast, and what the surrounding immune environment looks like. In some settings, necrosis signals aggressive, oxygen-starved tumor growth and predicts worse outcomes; in others, the spilling of cellular contents alerts the immune system to mount an attack against the cancer. This tension between harm and help runs through nearly every aspect of tumor necrosis, from what pathologists see under the microscope to how researchers are trying to exploit it therapeutically.
What Tumor Necrosis Actually Is
Necrosis, broadly, is a form of cell death in which the cell membrane breaks apart and the contents leak out into surrounding tissue. This is different from apoptosis, the tidy “programmed” cell death where cells shrink, package their debris neatly, and get quietly swept away without triggering much of an immune response. In tumors, necrosis tends to happen when rapidly dividing cancer cells outstrip their blood supply. The innermost cells, furthest from functional blood vessels, become starved of oxygen and nutrients. When enough of them die this way, pathologists can see dead zones, often at the core of the tumor, that look pale and structureless under a microscope.
The most common pattern is called coagulative necrosis, where the outlines of dead cells are preserved but the nuclei lose their staining. Over time, these regions can develop scar tissue, leftover blood residues, and “ghost cells” that make it hard to tell whether the necrosis arose spontaneously or was caused by treatment.1PubMed Central. Rethinking the Prognostic Role of Necrosis in Soft-Tissue Sarcoma: Multidisciplinary Insights from the Sarcoma Academy That distinction matters clinically because spontaneous necrosis and therapy-induced necrosis can carry very different implications for how a patient is doing.
Why Necrosis Often Signals Trouble
When necrosis shows up in a tumor that has not been treated yet, it usually means the cancer is growing so fast that it has outrun its own blood supply. That is a hallmark of aggressive biology. In osteosarcoma, for example, an older but influential study found that every patient whose untreated tumor showed more than 20 percent spontaneous necrosis died of the disease, while roughly a third of those with less than 20 percent necrosis became long-term survivors.2PubMed. Prognostic significance of spontaneous tumour necrosis in osteosarcoma Extensive spontaneous necrosis in that setting pointed to a tumor racing ahead so quickly that even its own cells could not keep up.
Glioblastoma tells a similar story. In a study of patients with this aggressive brain cancer, those whose tumors contained necrosis had somewhat shorter survival than those whose tumors did not. After accounting for patient age, functional status, and how much tumor was removed surgically, necrosis remained a statistically significant predictor of worse outcomes, though the actual survival gap was modest: around 10.9 months versus 12.5 months.3PubMed. Necrosis as a prognostic factor in glioblastoma multiforme The hypoxic, necrotic core of glioblastoma is now understood to be a key driver of the tumor’s resistance to treatment, activating molecular programs that promote new blood vessel formation, altered metabolism, and immune suppression within the tumor.4PubMed. Tumor microenvironment in glioblastoma: The central role of the hypoxic-necrotic core
In kidney cancer, the picture is more nuanced. Necrosis in renal cell carcinoma is generally considered a bad sign, yet near-total necrosis, above 95 percent, may actually be a favorable short-term indicator after adjusting for tumor stage, likely because it represents the tumor effectively destroying itself. On balance, though, the presence of necrosis alone is not a strong independent predictor of outcomes in kidney cancer.5PubMed Central. Prognostic relevance of extensive necrosis in renal cell carcinoma A large study of over 800 kidney cancer cases found that when necrosis was combined with the tumor’s grade, it meaningfully improved the ability to predict survival, dividing patients into distinct prognostic groups.6PubMed. Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution Necrosis alone did not tell the full story, but it sharpened the picture when read alongside other pathological features.
How Necrosis Fuels Tumor Growth
The reason spontaneous necrosis so often tracks with aggression is not just that it signals a fast-growing tumor. The necrotic process itself can actively make things worse. When cells rupture, they release molecules known as damage-associated molecular patterns, or DAMPs. In a healthy context, these molecules serve as distress signals that recruit immune cells to a site of injury. But in tumors, the chronic release of DAMPs can provoke a persistent inflammatory state that the cancer exploits, driving further tumor development and progression.7PubMed Central. Damage-associated molecular patterns in cancer: a double-edged sword
One of the key consequences is the recruitment of immune cells called macrophages. Macrophages are versatile: they can be fierce tumor killers or compliant tumor supporters, depending on how their local environment shapes them. In many cancers, macrophages drawn in by necrotic debris get reprogrammed by the tumor microenvironment into a supportive role, promoting new blood vessel formation, suppressing anti-tumor immune responses, and even helping cancer cells spread to distant sites.8PubMed Central. Macrophage Polarization States in the Tumor Microenvironment Researchers studying therapy-induced necrosis have pointed out this same mechanism: the macrophages that arrive in response to necrotic signals can produce growth factors and blood-vessel-promoting signals that actually accelerate tumorigenesis.9AACR Journals. The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment
The oxygen-starved environment around necrotic zones also triggers molecular programs driven by a factor called HIF-1alpha. This master regulator ramps up production of vascular endothelial growth factor (VEGF), a protein that stimulates the growth of new blood vessels into the tumor.10PubMed. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis In colorectal cancer, this hypoxia-driven cascade has been traced through a specific molecular pathway that promotes cancer cell proliferation, migration, and invasion.11PubMed Central. HIF1-driven TDP-43 stabilizes TRIP6 mRNA to drive angiogenesis and colorectal cancer progression under hypoxia So the zones of necrosis within a tumor are not just dead weight. They are active participants in making the surrounding living tumor cells more dangerous.
The Other Side: When Necrosis Helps Fight Cancer
If chronic, low-grade necrosis in an untreated tumor tends to feed the beast, the picture changes when necrosis is deliberately induced or occurs rapidly enough to overwhelm the tumor’s ability to co-opt the inflammatory response. The same DAMPs that sustain chronic inflammation in one scenario can, in another, set off a robust anti-tumor immune reaction.
One of these molecules, HMGB1, has been shown to act as an effective immune booster. When released from dying tumor cells, HMGB1 can promote the maturation and migration of dendritic cells, the immune system’s key antigen presenters, and support the activation and expansion of T cells that target the cancer.12AACR Journals. The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment – Section: Host Immune Reaction to Apoptosis, Autophagy, and Necrosis In the context of treatments aimed at established tumors, this immune-activating side of necrosis can become the dominant effect rather than the pro-tumorigenic one.
A particularly striking example comes from recent work on a procedure called TATE (transarterial tumor embolization), which deliberately kills tumor tissue by cutting off its blood supply. In patients with cancers that had stopped responding to immunotherapy, the wave of necrosis induced by TATE generated a massive expansion of anti-tumor T cells. Between 60 and 70 percent of the T cell clones detected after the procedure were entirely new, and some pre-existing T cell populations expanded by over a hundredfold. Patients who had failed checkpoint immunotherapy began responding again after this deliberate necrosis was triggered.13Journal for ImmunoTherapy of Cancer. Tumor necrosis-induced expansion of anti-tumor T cells enhanced the efficacy of immune checkpoint inhibitors (ICIs) and salvaged patients with immunotherapy-refractory cancers The necrosis essentially ripped open the tumor and presented its contents to the immune system in a way that reignited a stalled immune attack.
Necroptosis and the Push for Immunogenic Cell Death
Much of the excitement in this field right now centers on a specific form of programmed necrosis called necroptosis. Unlike the disorganized necrosis that happens when cells simply starve, necroptosis follows a defined molecular pathway, proceeding through proteins known as RIPK1, RIPK3, and MLKL. The end result is the same, the cell membrane ruptures and the contents spill out, but because the pathway is genetically encoded, it can potentially be switched on deliberately.
Most current cancer therapies kill tumor cells through apoptosis, which is largely immunologically quiet. Necroptosis, by contrast, generates potent signals that activate surrounding immune cells and boost the presentation of tumor-derived material to the adaptive immune system. A 2024 review in Nature Reviews Cancer described this as combining “cellular suicide and immune response approaches” and highlighted how necroptosis optimizes both the release of tumor antigens and the danger signals that tell immune cells those antigens are worth responding to.14PubMed. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
There is a catch, though. Research has also shown that necroptosis can promote cancer metastasis and even cause the death of anti-tumor T cells in some circumstances. Certain cancers have learned to escape necroptosis entirely by silencing the expression of RIPK3, one of the key proteins in the pathway.15PubMed Central. Necroptosis and Cancer So even this more controlled form of necrosis carries the same fundamental duality: it can be weaponized against cancer, but cancer can also adapt to weaponize it in return.
Experimental approaches to tipping the balance include nanoparticle-based drug delivery systems. One such system combined a natural compound called shikonin with chitosan-silver nanoparticles to trigger necroptosis in triple-negative breast cancer cells. The resulting cell death matured dendritic cells, increased infiltration of killer T cells into tumors, and suppressed regulatory T cells that otherwise shield the cancer. In preclinical models, this approach controlled both primary tumors and distant metastases.16PubMed. Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through RIPK3-triggered necroptotic immunogenic cell death Small-molecule drugs targeting the necroptosis pathway are also being explored as a way to bypass tumors’ resistance to conventional apoptosis-inducing treatments while keeping the immune-activating benefits intact.17PubMed Central. Targeting necroptosis in anticancer therapy: mechanisms and modulators
Engineered systems that activate RIPK3-driven necroptosis within tumors have shown promise in reshaping the tumor’s immune landscape: promoting the maturation of dendritic cells, shifting macrophages toward an anti-tumor profile, and reducing T cell exhaustion.18Biomedicine & Pharmacotherapy. Unleashing necroptosis: Transforming the tumor immune microenvironment for cancer therapy The idea is not just to kill tumor cells but to make their death useful for the immune system.
Tumor Lysis Syndrome: When Too Much Necrosis Becomes an Emergency
If the pro-tumorigenic effects of necrosis represent a slow-burning problem, tumor lysis syndrome is the acute, life-threatening version of too much tumor cell death at once. When a cancer responds dramatically to chemotherapy, immunotherapy, or radiation, the sudden breakdown of a large number of tumor cells can flood the bloodstream with their intracellular contents: potassium, phosphorus, uric acid, and other metabolites. The body’s normal systems for clearing this debris get overwhelmed.19PubMed. Tumor lysis syndrome in elderly
The resulting metabolic crisis can cause dangerous heart rhythm abnormalities from high potassium, kidney failure from uric acid crystals clogging the renal tubules, seizures from low calcium, and in severe cases, multiorgan failure.20PubMed. Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System Tumor lysis syndrome is most commonly associated with blood cancers like leukemia and lymphoma, which can involve enormous numbers of cancer cells that are exquisitely sensitive to treatment. But it can also occur in solid tumors that respond rapidly. The syndrome is a vivid reminder that even when tumor cell death is the therapeutic goal, the speed and scale at which it happens matter enormously. Oncologists routinely monitor for it and preemptively treat high-risk patients with hydration and medications to lower uric acid levels.
The Confusing Legacy of Tumor Necrosis Factor
The phrase “tumor necrosis” carries an extra layer of confusion because of a famous molecule that shares the name: Tumor Necrosis Factor, or TNF. When TNF was first described, it was celebrated as a soluble factor produced by the immune system that could destroy tumors, hence the name. Early researchers imagined it as a potential cancer cure. But decades of subsequent research revealed that TNF mainly functions as a broad pro-inflammatory cytokine, and its relationship with cancer is complicated at best.21PubMed Central. Tumor Necrosis Factor: What Is in a Name?
In high doses and delivered locally, TNF can indeed cause hemorrhagic necrosis of tumors, which is how it got its name. But systemically administered TNF turned out to be devastatingly toxic, causing shock-like symptoms. And in the chronic, lower concentrations found naturally in the tumor microenvironment, TNF often promotes inflammation that supports tumor survival and growth rather than destroying it. Today TNF is primarily known as a driver of inflammatory diseases like rheumatoid arthritis and Crohn’s disease, and the drugs that block it (anti-TNF therapies) are among the most widely prescribed biologics in medicine. The history of TNF is itself a microcosm of the broader lesson about tumor necrosis: what seems like it should be unambiguously anti-cancer can turn out to be anything but.
Necrosis in Imaging and Treatment Monitoring
Necrosis shows up on imaging scans, which gives clinicians a noninvasive way to track what is happening inside a tumor. On MRI, necrotic regions typically appear as areas with distinct signal characteristics compared to living tumor tissue. In preclinical imaging work, researchers tracking liver tumors in rats found that necrotic areas expanded as tumors grew rapidly: during early moderate growth, tumors were mostly solid with little necrosis, but once rapid expansion kicked in, the proportion of necrosis increased while viable tissue shrank.22PubMed Central. Diffusion-weighted magnetic resonance imaging using a preclinical 1 T PET/MRI in healthy and tumor-bearing rats Histological analysis confirmed that what the imaging showed as necrosis corresponded to actual dead tissue.
In clinical practice, a growing zone of necrosis on imaging after treatment may be a good sign, suggesting the therapy is killing tumor cells. But interpreting necrosis on scans is not straightforward. In triple-negative breast cancer, for instance, one study found that the presence of necrosis on MRI before chemotherapy did not predict whether patients would achieve a complete pathological response to treatment. None of the imaging measures of necrosis reliably distinguished responders from non-responders.23PubMed Central. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC) Necrosis on a scan is a data point, but its meaning depends on when it appears, what caused it, and which cancer is being evaluated.
Exploiting Necrotic Zones as Delivery Targets
One of the more creative therapeutic strategies involves using the necrotic core of tumors not as a problem to solve but as a feature to exploit. The oxygen-free environment inside necrotic tumor zones is inhospitable to most organisms, but it is perfect for certain bacteria that thrive without oxygen. Researchers have developed approaches using Clostridium spores, which naturally germinate and multiply only in anaerobic conditions, as vehicles for delivering therapeutic genes directly to tumors. Because the necrotic core of a solid tumor provides the specific oxygen-free conditions these bacteria need, they colonize tumors with remarkable specificity while leaving healthy tissue alone.24PubMed Central. Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery
This approach turns the very feature that makes aggressive tumors dangerous, their large necrotic cores, into a vulnerability that can be therapeutically targeted. The strategy is still in relatively early development, but it illustrates the broader principle that runs through the entire field: tumor necrosis is not inherently good or bad. It is a biological event whose consequences depend entirely on how you interact with it. Leave it alone and it usually feeds inflammation and growth. Direct the immune system’s attention to it and it can trigger powerful anti-tumor responses. Engineer a delivery system to exploit it and it becomes a homing beacon for precision therapies. The same dead tissue, read differently by different biological actors, produces opposite outcomes.
In melanoma research, scientists have found that under low-oxygen conditions, some tumor cells undergo patterned cell necrosis that creates spatial structures within the tumor, potentially laying groundwork for new blood supply channels.25PubMed. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma Even the architecture of how cells die and where they die within a tumor can have downstream consequences for how the cancer feeds itself. The geometry of necrosis, not just its presence or absence, influences tumor behavior in ways that researchers are only beginning to map.